All In Biotech

Drug Trial Radar · NCT05937386

Drug-Drug Interaction Study With AGMB-129 and Midazolam in Healthy Participants

An Open-Label, Fixed-Sequence, Drug-Drug Interaction Study in Healthy Participants to Evaluate the Effect of AGMB-129 on the Pharmacokinetics of Midazolam, a Sensitive Index Substrate of CYP3A4

Last checked: Nov 19, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Aug 9, 2023

Primary completion

Sep 6, 2023

Study completion Sep 6, 2023

Sponsor

Lead sponsor
Agomab Spain S.L.Industry
Sponsor type
Industry
First posted
Jul 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, fixed-sequence, Phase 1 study in healthy adult participants to evaluate the effect of AGMB-129 on the PK of a single dose of MDZ in healthy participants. A total of 14 participants will be enrolled and will receive study intervention in a fixed-sequence scheme. All IP will be administered orally and in fed conditions. The total duration of involvement for each participant, screening through follow-up, will be approximately 6 weeks.

Conditions

  • Healthy Volunteers

Interventions

  • AGMB-129Drug

    Oral capsule

  • MDZDrug

    Pre-filled oral syringes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax for MDZTime frame: Day 1 to Day 13
  2. Cmax for 1-OH-midazolamTime frame: Day 1 to Day 13
  3. AUC0-∞ for MDZTime frame: Day 1 to Day 13
  4. AUC0-∞ for 1-OH-midazolamTime frame: Day 1 to Day 13

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SGS Belgium

    Edegem, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.